Literature DB >> 26037731

The Impact of Inpatient Versus Outpatient Initiation on Early Warfarin Dosing.

Scott E Kasner1, Le Wang, Benjamin French, Steven R Messe, Richard Horenstein, Emile R Mohler, James A S Muldowney, Jonas Ellenberg, Stephen E Kimmel.   

Abstract

BACKGROUND AND OBJECTIVES: Dosing algorithms for warfarin incorporate clinical and genetic factors but may not account for the numerous comorbidities affecting patients who start warfarin while hospitalized. We aimed to determine whether these algorithms perform differently when warfarin is initiated for inpatients compared with outpatients. PATIENTS AND METHODS: We analyzed a prospective cohort of 1015 participants from the Clarification of Optimal Anticoagulation through Genetics (COAG) trial who were randomized to either pharmacogenetically or clinically guided warfarin dosing algorithms. Clinicians and participants were blinded to dose during the first 28 days. We compared groups, based on location at the time of the first warfarin dose request, in relation to the following outcomes: percentage of time in the therapeutic international normalized ratio (INR) range (PTTR) during the first 4 weeks, time to first therapeutic INR, time to maintenance dose, and the difference between predicted and observed maintenance doses.
RESULTS: A total of 527 participants started warfarin as inpatients and 488 as outpatients. There was no difference in PTTR based on location: 43.2 % for inpatient versus 47.4 % for outpatient initiation [mean adjusted difference -2.2 %; 95 % confidence interval (CI) -5.9 to 1.6]. Similarly, there were no differences in time to first therapeutic INR [hazard ratio (HR) 1.06; 95 % CI 0.91-1.24] or to maintenance dose (HR 0.96; 95 % CI 0.81-1.14). There was no evidence of interaction between study intervention (pharmacogenetically vs. clinically guided therapy) and location of initiation for these main outcomes. The difference between predicted and observed maintenance doses was similar for both locations.
CONCLUSION: The warfarin dosing algorithms performed similarly for subjects who initiated warfarin as inpatients and outpatients, regardless of whether dosing was pharmacogenetically or clinically guided.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26037731      PMCID: PMC4508217          DOI: 10.1007/s40256-015-0126-3

Source DB:  PubMed          Journal:  Am J Cardiovasc Drugs        ISSN: 1175-3277            Impact factor:   3.571


  18 in total

1.  Inpatient warfarin: experience with a pharmacist-led anticoagulation management service in a tertiary care medical center.

Authors:  Sara Fowler; Michael P Gulseth; Colleen Renier; James Tomsche
Journal:  Am J Health Syst Pharm       Date:  2012-01-01       Impact factor: 2.637

2.  Inpatient warfarin management: pharmacist management using a detailed dosing protocol.

Authors:  Nancy L Dawson; Ivan E Porter; Dusko Klipa; William R Bamlet; Mary Ann Hedges; Michael J Maniaci; Jason Persoff; Archana Roy; Alden V Patel
Journal:  J Thromb Thrombolysis       Date:  2012-02       Impact factor: 2.300

3.  Integration of genetic, clinical, and INR data to refine warfarin dosing.

Authors:  P Lenzini; M Wadelius; S Kimmel; J L Anderson; A L Jorgensen; M Pirmohamed; M D Caldwell; N Limdi; J K Burmester; M B Dowd; P Angchaisuksiri; A R Bass; J Chen; N Eriksson; A Rane; J D Lindh; J F Carlquist; B D Horne; G Grice; P E Milligan; C Eby; J Shin; H Kim; D Kurnik; C M Stein; G McMillin; R C Pendleton; R L Berg; P Deloukas; B F Gage
Journal:  Clin Pharmacol Ther       Date:  2010-04-07       Impact factor: 6.875

4.  Efficacy and safety of a pharmacist-managed inpatient anticoagulation service for warfarin initiation and titration.

Authors:  Y M Wong; Y-N Quek; J C Tay; V Chadachan; H K Lee
Journal:  J Clin Pharm Ther       Date:  2010-11-12       Impact factor: 2.512

5.  Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients.

Authors:  E Pautas; C Moreau; I Gouin-Thibault; J-L Golmard; I Mahé; C Legendre; E Taillandier-Hériche; B Durand-Gasselin; A-M Houllier; P Verrier; P Beaune; M-A Loriot; V Siguret
Journal:  Clin Pharmacol Ther       Date:  2009-09-30       Impact factor: 6.875

6.  A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II).

Authors:  Jeffrey L Anderson; Benjamin D Horne; Scott M Stevens; Scott C Woller; Kent M Samuelson; Justin W Mansfield; Michelle Robinson; Stephanie Barton; Kim Brunisholz; Chrissa P Mower; John A Huntinghouse; Jeffrey S Rollo; Dustin Siler; Tami L Bair; Stacey Knight; Joseph B Muhlestein; John F Carlquist
Journal:  Circulation       Date:  2012-03-19       Impact factor: 29.690

Review 7.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.

Authors:  J A Johnson; L Gong; M Whirl-Carrillo; B F Gage; S A Scott; C M Stein; J L Anderson; S E Kimmel; M T M Lee; M Pirmohamed; M Wadelius; T E Klein; R B Altman
Journal:  Clin Pharmacol Ther       Date:  2011-09-07       Impact factor: 6.875

8.  Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.

Authors:  Jeffrey L Anderson; Benjamin D Horne; Scott M Stevens; Amanda S Grove; Stephanie Barton; Zachery P Nicholas; Samera F S Kahn; Heidi T May; Kent M Samuelson; Joseph B Muhlestein; John F Carlquist
Journal:  Circulation       Date:  2007-11-07       Impact factor: 29.690

9.  Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Jack Ansell; Jack Hirsh; Elaine Hylek; Alan Jacobson; Mark Crowther; Gualtiero Palareti
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

10.  Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.

Authors:  Benjamin French; Jungnam Joo; Nancy L Geller; Stephen E Kimmel; Yves Rosenberg; Jeffrey L Anderson; Brian F Gage; Julie A Johnson; Jonas H Ellenberg
Journal:  Trials       Date:  2010-11-17       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.